Analysis of the PD-L1 Expression and Relevant Clinical Factors in Advanced Colorectal Cancer

DOI: https://doi.org/10.62517/jmhs.202305401

Author(s)

Yulin Li

Affiliation(s)

The Third Affiliated Hospital of Kunming Medical University, Yunnan, China

Abstract

This study aims to investigate the relation among PD-L1 expression and clinical, pathological and labo\expression, therapeutic effect and OS after chemotherapy with first-line chemotherapy. To reach that goal, 96 patients with advanced colorectal cancer were collected and analyzed retrospectively during the period from January 2016 to December 2016.

Keywords

PD-L1; Pathological; Cancer

References

[1] Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target[J]. Proc Natl Acad Sci U S A, 2004, 101(49): 17174-9. [2] Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer[J].Clin Cancer Res, 2005, 11(8): 2947-53. [3] 64Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety,clinical activity, pharmacodynamics and immunologic correlates[J]. J Clin Oncol, 2010, 28(19): 3167-75. [4] Bae, SU; Jeong, WK; Baek, SK; et al.Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer.[J].Oncol Lett.2018,16(4):5214-5222